A small group of people with Parkinson's disease had been pleading for months with the biotechnology company Amgen: Let them resume taking an experimental drug that the patients said had helped them but which the company said was ineffective and possibly dangerous.
"Mutations in this gene could become the most important cause of disease susceptibility for Parkinson's disease identified so far." Scientists believe they have pinpointed a tiny genetic flaw that is to blame for around four percent of all cases of Parkinson's, a discovery that could eventually open the way, albeit controversially, to genetic testing for the disease.
